Latest Breaking News On - International myeloma working group - Page 5 : comparemela.com

Anito-Cel Elicits Responses With Manageable Safety in Relapsed/Refractory Multiple Myeloma

Anitocabtagene autoleucel showcased early efficacy with acceptable toxicity in patients with relapsed and/or refractory multiple myeloma even in those with high-risk features.

United statesMatthew frigaultInternational staging systemInternational myeloma working groupCellular therapy service at massachusettsHarvard medical schoolMyeloma working groupCellular therapy serviceMassachusetts general hospitalAnitocabtagene autoleucelPatients with relapsed and or refractory multiple myeloma

C4 Therapeutics (CCCC) Reports Positive Data from CFT7455 Phase 1 Trial

C4 Therapeutics (CCCC) Reports Positive Data from CFT7455 Phase 1 Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Len reynoTherapeutics incInternational myeloma working groupStable diseasePartial responseStringent complete responseVery good partial responseData presentations

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesLoraine spreenLen reynoCourtney solbergExchange commissionInternational myeloma working groupTherapeutics incCorporate communications patient advocacyAnnounces positive dataRefractory multipleOptimal dosing scheduleWell toleratedPromising signsImmunomodulatory effectsNovel multiple myeloma agentsDexamethasone results

Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone

Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone
finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.

Czech republicUnited statesFrance generalUnited kingdomPeterc adamsonSally bainPieter sonneveldNathalie phamFelix lauscherCorentine driancourtTarik elgoutniEva schaefer jansenEuropean myeloma networkDepartment of molecular biotechnologyInternational myeloma working groupEuropean union

New BiTE Agents Provide Effective Options for Treatment of Relapsed/Refractory Multiple Myeloma

Seven new agents have received FDA approval since October 2022.

Andersonl jrJanssen biotech incBristol myers squibbInternational myeloma working groupJanssen biotechRisk evaluationMitigation strategyPractice guidelines